Physician profile

Gary Madden

Obstetrics & Gynecology · Midland, TX

NPI 1386757136

$3,314.75

in general payments reported to CMS, 2019-2025

38 companies · $244 in 2025

The $244 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).

See the full distribution for Obstetrics & Gynecology

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$727.68
Education$14.76

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Abbvie INC. $824.56 2019-2024
Bayer Healthcare Pharmaceuticals INC. $343.16 2019-2023
Amgen INC. $298.59 2019-2023 Prolia, Evenity
Astellas Pharma US INC $283.24 2019-2025 Veozah
Radius Health, INC. $147.93 2019-2025 Tymlos
Daiichi Sankyo INC. $127.95 2022-2023 Injectafer
Exeltis, USA INC. $120.63 2019-2022
Hologic Sales and Service, LLC $111.99 2021-2025 Myosure Tissue Removal Device, Novasure
Arbor Pharmaceuticals, INC. $104.17 2019-2021
Axonics, INC. $98.11 2021-2023 Axonics
Takeda Pharmaceuticals U.S.A., INC. $70.34 2019-2021
Allergan, INC. $65.27 2019-2020
Pharmacosmos Therapeutics INC. $64.07 2021-2023 Monoferric
Vivus LLC $56.85 2020-2022
Lilly USA, LLC $53.46 2022-2025 Zepbound
Show all 37 companies
CompanyGeneral paymentsYearsTop products
Organon LLC $49.73 2022-2024 Nexplanon
Vertical Pharmaceuticals, LLC $49.50 2019
Biogen, INC. $47.31 2025 Zurzuvae
Coopersurgical, INC. $45.90 2020
Sumitomo Pharma America, INC. $43.52 2025 Myfembree
Lupin INC. $35.86 2019
Mayne Pharma Commercial LLC $34.39 2023
Avion Pharmaceuticals $29.44 2020-2021
Therapeuticsmd, INC. $29.26 2022
Ethicon US, LLC $25.86 2022
Ortho-Clinical Diagnostics, INC. $21.49 2021
Scynexis, INC. $15.01 2022
Minerva Surgical, INC $13.61 2025
Pfizer INC. $13.49 2024
Exact Sciences Corporation $13.08 2024 Cologuard Collection Kit
Genentech USA, INC. $12.96 2020
Currax Pharmaceuticals LLC $12.48 2021
Mallinckrodt Enterprises LLC $12.46 2019
Amag Pharmaceuticals, INC. $11.86 2019
Assertio Therapeutics, INC. $11.04 2020
Molnlycke Health Care US, LLC $10.42 2024 Mepilex Border Post-Op Ag, Avance, Mepilex Border Post-Op
Intuitive Surgical, INC. $5.76 2023 Da Vinci Surgical System

1 company reported research payments only; those appear in the research section below.

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

Research and ownership

$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Gary Madden

$3,314.75

in general payments reported 2019-2025

Years
2019-2025
Top company
Abbvie INC.
Context
The $244 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).

https://glasscript.com/doctor/198395/gary-madden

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Download CSV

The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.